Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for Gonadorelin

9 records for Gonadorelin, of which 2 are published trials.

Showing 0 records on this page

Records

9 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
GNRH-DIAGNOSTICGonadorelinReportedDiagnostic accuracyModerate
GNRH-PULSATILE-HHGonadorelinReportedSingle-arm open-labelModerate
GNRH-DIAGNOSTIC-REGIONAL-JPprogramme recordGonadorelinPhase 3ReportedRandomised, double-blind, placebo-controlledVery low
GNRH-PULSATILE-HH-PKprogramme recordGonadorelinPhase 1ReportedPhase 1 ascending doseVery low
GNRH-DIAGNOSTIC-BODY-COMPprogramme recordGonadorelinReportedRandomised, double-blind, placebo-controlledVery low
GNRH-PULSATILE-HH-RENAL-IMPprogramme recordGonadorelinPhase 1ReportedPhase 1 ascending doseVery low
GNRH-DIAGNOSTIC-QOLprogramme recordGonadorelinReportedRandomised, double-blind, placebo-controlledVery low
GNRH-PULSATILE-HH-HEPATIC-IMPprogramme recordGonadorelinPhase 1ReportedPhase 1 ascending doseVery low
GNRH-PULSATILE-HH-DDIprogramme recordGonadorelinPhase 1ReportedRandomised crossoverVery low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.